ITG Isotopes Technologies Garching GmbH is a company of the ITM Group. ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Furthermore, ITM and its subsidiaries are developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases.

ITG GmbH offers radioisotopes for clinical applications as well as research purposes. They have therefore established a GMP manufacturing of a first-in-class radionuclides and -generator platform for the development of a new generation of targeted cancer diagnostics and therapies. Since 2007 the name ITG Isotopes Technologies Garching GmbH has stood for the highest level of quality and reliability in the sourcing, processing, radiolabeling and sales of radionuclides and for the marketing of devices. ITG´s unrivaled logistics network allows guaranteed shipment within 24 hrs (Europe) and 72 hrs (Overseas) respectively. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta®.

EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. This drug approval is an important milestone for the ITM Group. Their main objectives, together with their scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.